Price T Rowe Associates Inc Aligos Therapeutics, Inc. Transaction History

Price T Rowe Associates Inc

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Aug 15, 2022	SELL	$1.04 - $2.14 $23,482 - $48,319	-22,579 Closed	0 $0
Q1 2022 May 16, 2022	BUY	$2.08 - $12.2 $1,040 - $6,100	500 Added 2.26%	22,579 $49,000
Q4 2021 Feb 14, 2022	SELL	$11.48 - $17.69 $59,696 - $91,988	-5,200 Reduced 19.06%	22,079 $262,000
Q3 2021 Nov 15, 2021	BUY	$14.57 - $17.72 $713 - $868	49 Added 0.18%	27,279 $423,000
Q2 2021 Aug 16, 2021	BUY	$20.3 - $33.6 $552,769 - $914,928	27,230 New	27,230 $555,000

47.3M

1.4K

300

Ticker ALGS
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 39,717,000
Market Cap $326M
Description
Aligos Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses to develop novel therapeutics to address unmet medical needs in viral and liver diseases. Its lead drug candidate is ALG-010133, a s-antigen transport-inhibiting oligonucleotide polymer that is in Phase Ib clinical trial for the treatment of chronic hepatitis B (CHB);...

Get notified when there are updates to the investment portfolio of Price T Rowe Associates Inc , based on Form 13F filings with the SEC.

Stay updated on Price T Rowe Associates Inc with notifications on news.